Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Sexual Dysfunction, Physiological 1Non-Small Cell Lung Cancer ALK-positive 1Neuroblastoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lung Neoplasms 1Lung Diseases 1Hyperlipidemias 1Eunuchism 1Erectile Dysfunction 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Surveys and Questionnaires 15Radiosurgery 14Magnetic Resonance Imaging 11Magnetic Resonance Spectroscopy 10Neuropsychological Tests 8Radiotherapy 7Radiation 4Blood Specimen Collection 4Patient Reported Outcome Measures 3sacituzumab govitecan 2Trastuzumab 2Surgical Procedures, Operative 2Quality of Life 2Physical Examination 2Phlebotomy 2Perfusion Magnetic Resonance Imaging 2Lead 2Lapatinib 2Interviews as Topic 2Immunotherapy 2Drug Therapy 2Data Collection 2Brain Mapping 2Bevacizumab 2Amplified Fragment Length Polymorphism Analysis 2Aminolevulinic Acid 2trastuzumab deruxtecan 1pembrolizumab 1osimertinib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Brain Neoplasms × lorlatinib × Clear all
NCT06410040 2024-05-10

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Sichuan Cancer Hospital and Research Institute

Active not recruiting
28 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡